Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment.

Giorgini F, Möller T, Kwan W, Zwilling D, Wacker JL, Hong S, Tsai LC, Cheah CS, Schwarcz R, Guidetti P, Muchowski PJ.

J Biol Chem. 2008 Mar 21;283(12):7390-400. Epub 2007 Dec 13.

2.
3.

Huntington disease: new insights on the role of huntingtin cleavage.

Wellington CL, Leavitt BR, Hayden MR.

J Neural Transm Suppl. 2000;(58):1-17. Review.

PMID:
11128600
4.

Selective degeneration in YAC mouse models of Huntington disease.

Van Raamsdonk JM, Warby SC, Hayden MR.

Brain Res Bull. 2007 Apr 30;72(2-3):124-31. Epub 2006 Nov 16. Review.

PMID:
17352936
5.

Rodent genetic models of Huntington disease.

Heng MY, Detloff PJ, Albin RL.

Neurobiol Dis. 2008 Oct;32(1):1-9. doi: 10.1016/j.nbd.2008.06.005. Epub 2008 Jun 26. Review.

PMID:
18638556
6.

Transcriptional abnormalities in Huntington disease.

Sugars KL, Rubinsztein DC.

Trends Genet. 2003 May;19(5):233-8. Review.

PMID:
12711212
7.

Huntington disease and the huntingtin protein.

Zheng Z, Diamond MI.

Prog Mol Biol Transl Sci. 2012;107:189-214. doi: 10.1016/B978-0-12-385883-2.00010-2. Review.

PMID:
22482451
8.

Polyglutamine expansion and Huntington's disease.

Bates GP, Mangiarini L, Wanker EE, Davies SW.

Biochem Soc Trans. 1998 Aug;26(3):471-5. Review. No abstract available.

PMID:
9765898
9.

Mutant huntingtin can paradoxically protect neurons from death.

Zuchner T, Brundin P.

Cell Death Differ. 2008 Mar;15(3):435-42. Epub 2007 Nov 2. Review.

10.

Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.

Truant R, Atwal RS, Burtnik A.

Prog Neurobiol. 2007 Nov;83(4):211-27. Epub 2007 Jan 22. Review.

PMID:
17240517
11.

Progress and challenges in RNA interference therapy for Huntington disease.

Harper SQ.

Arch Neurol. 2009 Aug;66(8):933-8. doi: 10.1001/archneurol.2009.180. Review. Erratum in: Arch Neurol. 2009 Oct;66(10):1272.

PMID:
19667213
12.

Huntingtin in health and disease.

Young AB.

J Clin Invest. 2003 Feb;111(3):299-302. Review. No abstract available.

13.

Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases.

Krainc D.

Arch Neurol. 2010 Apr;67(4):388-92. doi: 10.1001/archneurol.2010.40. Review.

PMID:
20385902
14.

Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis.

Glajch KE, Sadri-Vakili G.

J Huntingtons Dis. 2015;4(1):1-15. doi: 10.3233/JHD-159001. Review.

PMID:
25813218
15.

Polyglutamine disease: acetyltransferases awry.

Hughes RE.

Curr Biol. 2002 Feb 19;12(4):R141-3. Review.

16.

Modeling Huntington disease in yeast: perspectives and future directions.

Mason RP, Giorgini F.

Prion. 2011 Oct-Dec;5(4):269-76. doi: 10.4161/pri.18005. Epub 2011 Oct 1. Review.

17.

Huntingtin: here, there, everywhere!

Marques Sousa C, Humbert S.

J Huntingtons Dis. 2013;2(4):395-403. doi: 10.3233/JHD-130082. Review.

PMID:
25062728
18.

Involvement of kynurenines in Huntington's disease and stroke-induced brain damage.

Stone TW, Forrest CM, Stoy N, Darlington LG.

J Neural Transm (Vienna). 2012 Feb;119(2):261-74. doi: 10.1007/s00702-011-0676-8. Epub 2011 Jun 22. Review.

PMID:
21695417
19.

Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology.

Parrott JM, O'Connor JC.

Front Psychiatry. 2015 Aug 20;6:116. doi: 10.3389/fpsyt.2015.00116. eCollection 2015. Review.

Supplemental Content

Support Center